stockrowMediciNova, Inc.
MNOV Healthcare Biotechnology
MediciNova, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $409,700.00, down 59.0% from fiscal 2023.
- Revenue
- +240.6%
- EPS
- +28.6%
- Free cash flow
- +16.8%
Quarter to June 2026, against a year earlier
Follow MNOV
Alert me
MediciNova, Inc. (MNOV) EV/Sales
As of 6 November 2026, MediciNova, Inc. (MNOV) trades at a EV/Sales of 50.5×. Over the past ten years it has ranged from 0.0× (March 2021) to 157× (September 2026); the current reading is higher than 97% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 23.7× | 775.63% |
| FY2023 | 2.7× | (53.71%) |
| FY2021 | 5.9× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 43.0× | (36.07%) |
| Mar 2026 | 67.2× | 183.13% |
| Dec 2025 | 23.7× | 3.46% |
| Sep 2025 | 22.9× | 295.74% |
| 4 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| OKYO OKYO Pharma Limited Sponsored ADR compare | n/m |
| TNYA Tenaya Therapeutics, Inc. compare | n/m |
| ACRV Acrivon Therapeutics, Inc. compare | n/m |
| CLLS Cellectis S.A. compare | 0.2× |
| CSBR Champions Oncology, Inc. compare | 1.0× |
| RANI Rani Therapeutics Holdings, Inc. compare | 12.6× |
| NRXS Neuraxis, Inc. compare | 12.8× |
| NTRB Nutriband Inc. compare | 39.8× |
| MNOV MediciNova, Inc. | 50.5× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)